27th week of 2020 patent applcation highlights part 10 |
Patent application number | Title | Published |
20200206236 | Protection of Cells from Degeneration and Treatment of Geographic Atrophy - Therapeutic uses P2X | 2020-07-02 |
20200206237 | NOVEL COMPOUNDS - The invention is directed to compounds of formula (I): | 2020-07-02 |
20200206238 | TREATMENT FOR CELLULITIS AND PRE-OPERATIVE TREATMENT - A composition for the treatment of cellulitis is provided that includes an antibiotic. The composition may also include an analgesic, an anaesthetic, or a combination thereof. A method use is also provided by which the composition is applied topically or to affected skin. A method of use is also provided prior to a medical procedure involving an incision through the skin of a patient in a predetermined area, the method including the application, to the predetermined area and prior to the procedure of the composition. | 2020-07-02 |
20200206239 | INHIBITION OF AMINOCYLASE 3 (AA3) IN THE TREATMENT OF CANCER - The current methods and compositions provide for therapeutic approaches to treating hepatocellular carcinoma (HCC) and other types of cancer including, for example, pancreatic and colon cancer. Accordingly, certain aspects of the disclosure relates to methods and compositions for treating HCC, pancreatic and colon cancer using one or more small molecule inhibitors disclosed herein. In certain embodiments, the small molecule inhibitor is a benzothiazine, a sulfonamide, a thiazolidinone or other chemical compound. | 2020-07-02 |
20200206240 | DIETARY SUPPLEMENT - A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine, sakae naa, and optionally, at least one of kava, CDP Choline, and Alpha GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter. | 2020-07-02 |
20200206241 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE - The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions. | 2020-07-02 |
20200206242 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS - According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy. | 2020-07-02 |
20200206243 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY - This invention provides for a method of h eating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof. In some embodiments, the method includes the proviso that the patient not be otherwise in need of treatment with a glucocorticoid and a glucocorticoid receptor antagonist. The treatment method can increase the patient's morning or basal cortisol level to at least about 12 μg/dL or a standard control level, and in turn, expedite significantly the recovery of the HPA axis. The method provided herein can improve health outcomes and life-threatening complications associated with secondary adrenal insufficiency. | 2020-07-02 |
20200206244 | TREATMENT OF DEMYELINATING DISEASES - Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration. | 2020-07-02 |
20200206245 | MAINTENANCE OF AGING MUSCLE TISSUE - A method of improving or maintaining muscle strength of aging muscle tissue. | 2020-07-02 |
20200206246 | COMPOSITION AND USES THEREOF - The present invention relates to compositions for inhibiting inflammation. The composition can comprise one or more natural products in the form of a nutraceutical or functional food. The present invention further relates to the combinatorial use of nutritional supplements and nutraceuticals for the prevention and/or treatment of sterile inflammation and conditions associated with sterile inflammation. | 2020-07-02 |
20200206247 | ORAL B12 THERAPY - Methods of normalizing vitamin B | 2020-07-02 |
20200206248 | COMBINED MEDICINAL PREPARATION FOR TREATING VIRAL INFECTIONS - The present invention relates to a novel combination drug in a solid oral dosage form comprising, as one of the three active ingredients, elsulfavirine sodium that may be suitable for medical use when treating viral infections including HIV and HBV. | 2020-07-02 |
20200206249 | PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT - Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy. | 2020-07-02 |
20200206250 | SYNTHETIC COMPOSITION FOR REDUCING ALLERGY SYMPTOMS - This invention relates to a method and composition for inducing allergen tolerance in a patient suffering from an atopic allergy or allergic asthma; hence reducing allergy symptoms in these patients. | 2020-07-02 |
20200206251 | METHODS FOR PREVENTING OR MITIGATING ACUTE ALLERGIC RESPONSES USING HUMAN MILK OLIGOSACCHARIDES - A method for preventing or mitigating an acute allergic response in a subject is disclosed. The method includes a step of administering a nutritional composition to the subject. The nutritional composition includes at least one of an acidic or a neutral HMO, but does not include an N-acetyl-lactosamine. | 2020-07-02 |
20200206252 | USE OF RIBOSE IN FIRST RESPONSE TO ACUTE MYOCARDIAL INFARCTION - D-ribose is administered to patients suffering an acute myocardial infarction during first response care, in order to prevent cardiac compromise. In those patients able to ingest fluids, two to five grams of D-ribose is administered orally. In a patients unable to ingest fluids, or in a patient with and intravenous line, pyrogen-free D-ribose is administered intravenously at a rate of 50-300 mg/kg/hour. | 2020-07-02 |
20200206253 | FIXED-DOSE PHARMACEUTICAL COMPOSITION COMPRISING RIFABUTIN, CLARITHROMYCIN, AND CLOFAZIMINE - Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, | 2020-07-02 |
20200206254 | METHODS FOR REDUCING OR SHUTTING DOWN LACTATION IN NON-HUMAN MAMMALS AND REAGENTS THEREFOR - The disclosure relates generally to methods and reagents for reducing or shutting down lactation in a non-human mammalian subject. In particular, the disclosure relates to a method of reducing or shutting down lactation in a non-human mammalian subject by administering to the subject by intramammary infusion an agent which activate the OAS2 signalling pathway or induce expression of OAS2. In some examples, the methods and reagents of the disclosure may be useful for the prevention of mastistis in a non-human mammalian subject, such as a dairy cow. | 2020-07-02 |
20200206255 | MANIPULATION OF EIF3 TO MODULATE REPEAT ASSOCIATED NON-ATG (RAN) TRANSLATION - Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure relates to methods for treating a subject having a disease associated with RAN protein translation by administering the subject a modulator of eIF3 or an eIF3 subunit, or an antibody that bind to a RAN protein. | 2020-07-02 |
20200206256 | METHODS OF TREATMENT OF CANCER WITH REDUCED UBB EXPRESSION - The present invention provides compositions comprising a UBC antagonist and methods of use thereof for treating cancer in a patient. In some embodiments, the cancer patient may have a reduced expression level of a UBB gene product. Further provided are reagents and methods for detection of a UBB and/or UBC gene product. | 2020-07-02 |
20200206257 | HOMOGENEOUS POLYSACCHARIDE ESP-B4, DERIVED FROM HERBA EPHEDRA, PREPARATION METHOD AND MEDICAL USE THEREOF - Provided is a homogeneous polysaccharide ESP-B4, method for producing the same and use thereof. The ESP-B4 is a polysaccharide monomer, which is isolated from the traditional Chinese medicine | 2020-07-02 |
20200206258 | LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions. | 2020-07-02 |
20200206259 | POLYMER GLUCAN HAVING LOW DIGESTION RATE - One purpose of the present invention is to provide a high molecular weight glucan having both properties low digestion rate and high digestibility. A high molecular weight glucan that has property digested slowly and contains almost no indigestible ingredients is produced by enzymatic reactions of (1) a specific concentration of branching enzyme and (2) 4-α-glucanotransferase and/or an exo-type amylase to a branched glucan used as a substrate. | 2020-07-02 |
20200206260 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION - Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. | 2020-07-02 |
20200206261 | COMPOSITION AND METHODS FOR GENERATING AND SUSTAINING MOLECULAR HYDROGEN (H2) IN AQUEOUS SYSTEMS - Provided are compositions, methods, and solutions for generating aqueous glucomannan solutions with hydrogen compositions greater than 100 parts per billion. Said glucomannan solutions have application in nutritional, therapeutic, and energy fields. | 2020-07-02 |
20200206262 | Pharmaceutical Preparation Containing Selenite or Selenite-Containing Compounds for Treating Cervical Dysplasia or Carcinomas - The invention relates to compositions containing selenite-containing compounds and pharmaceutically acceptable acids, selected from citric acid, acetic acid, malic acid, carbonic acid, sulphuric acid, nitric acid, hydrochloric acid, fruit acids or mixtures thereof, for use for treating cervical inflammations, dysplasia and/or carcinomas. The invention further relates to methods of using such compositions. | 2020-07-02 |
20200206263 | HYPOCHLOROUS ACID FORMULATIONS AND METHODS FOR TREATING SKIN CONDITIONS - The present invention in various aspects and embodiments provides methods and formulations for treating inflammatory conditions of the skin and/or conditions involving compromised skin barrier function. Such diseases include blistering diseases of the skin, hereditary defects in skin barrier function, hyperproliferative conditions involving the skin, conditions associated with aging or damaged skin, immunological disorders involving the skin, among others. | 2020-07-02 |
20200206264 | METHODS OF TREATMENT USING TOPICAL COPPER ION FORMULATIONS - Provided herein are topical formulations containing copper ions and methods of treating radiation dermatitis, damage caused by radiation therapy, or other radiation-induced damage conditions in various areas of the body using such formulations. Methods of treating radiation dermatitis using topical copper ion treatments are provided. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension is combined with various carriers to form the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided. | 2020-07-02 |
20200206265 | Methods of Preparing T Cells for T Cell Therapy - Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy. | 2020-07-02 |
20200206266 | USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA - The invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors. | 2020-07-02 |
20200206267 | ALLOGENEIC CAR-T PLATFORM USING HLA-MATCHED BANK OF IPSCS, AND RELATED COMPOSITIONS, SYSTEMS, AND METHODS - Presented herein are systems and methods of producing “universal” and/or “off-the-shelf” CAR-T compositions suitable for cancer therapy to be administered to one or more individuals. A CAR-T composition is a composition comprising one or more types of chimeric antigen receptor T cells (CAR-T). The iPSCs and/or cell lines, and any iPSC-derived CAR-T compositions derived therefrom, are identified as compatible with one or more individuals using an identification of a cell type indicative of compatibility (e.g., HLA match and/or ABO blood match and/or RHD blood match). The compatible cells are then retrieved from a managed HLA-indexed (and/or otherwise indexed) repository or are derived from a biological sample of a donor. The retrieved compatible cells are then used to derive iPSC-derived CAR-T compositions, wherein the derived compositions are suitable for therapy of one or more individuals. | 2020-07-02 |
20200206268 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-07-02 |
20200206269 | PRODUCTION OF ENUCLEATED RED BLOOD CELLS AND USES THEREOF - Multi-step methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express fusion proteins comprising an antigen binding protein which allows the red blood cell to bind a toxin or an antigen of a pathogen. Also described herein are methods for neutralizing a toxin or pathogen in a subject by administering enucleated red blood cells that express any of the fusion proteins provided herein. | 2020-07-02 |
20200206270 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTISM SPECTRUM DISORDER - Provided herein are compositions, uses thereof, and methods for treating Autism or Autism Spectrum Disorder (ASD) in a subject in need thereof, wherein the compositions comprise a whey protein isolate and/or whey protein concentrate. | 2020-07-02 |
20200206271 | COMBINATORIAL CANCER IMMUNOTHERAPY - Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer. | 2020-07-02 |
20200206272 | TREATMENT AGENT FOR EPIDERMOLYSIS BULLOSA - A cell product for treatment of epidermolysis bullosa, comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. Preferably, the epidermolysis bullosa is epidermolysis bullosa simplex, junctional epidermolysis bullosa, or dystrophic epidermolysis bullosa. | 2020-07-02 |
20200206273 | METHOD FOR CHEMOSELECTION - A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity. | 2020-07-02 |
20200206274 | USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA - Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae. | 2020-07-02 |
20200206275 | COLLAGEN ENCAPSULATION OF INSULIN-PRODUCING CELLS - Compositions comprising collagen and insulin-producing cells are provided. Processes for making such a collagen and insulin-producing cell compositions are also provided. Methods for controlling, or lowering blood glucose levels and treating metabolic disorders in mammals, including type 1 diabetes, with such compositions are further provided. Methods to prolong insulin-producing cell viability and function in vitro or during transport are also provided. | 2020-07-02 |
20200206276 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases. | 2020-07-02 |
20200206277 | AMMONIA OXIDIZING MICROORGANISMS FOR DISPERSING BIOFILMS - A method for degrading a biofilm on a surface is provided. A method of preventing formation of a biofilm on a surface is provided. The method includes administering, e.g., applying, ammonia oxidizing microorganisms, e.g., a preparation comprising ammonia oxidizing bacteria, to the surface. Preparations comprising ammonia oxidizing microorganisms for biofilm treatment are also provided. | 2020-07-02 |
20200206278 | AMMONIA OXIDIZING MICROORGANISMS FOR THE TREATMENT OF PULMONARY HYPERTENSION - A method of treating pulmonary hypertension in a subject is provided. The method comprises administering a preparation comprising ammonia oxidizing microorganisms to the subject, thereby treating the pulmonary hypertension. Related preparations, kits, and devices also provided. | 2020-07-02 |
20200206279 | AMMONIA OXIDIZING MICROORGANISMS FOR USE AND DELIVERY TO THE UROGENITAL SYSTEM - Ammonia oxidizing microorganism preparations for delivery to the urogenital system, kits including ammonia oxidizing preparations for delivery to the urogenital system, and devices for administering ammonia oxidizing preparations to the urogenital system are provided. Methods of introducing ammonia oxidizing microorganisms to the urogenital system are provided. Methods of treating disorders, including urogenital disorders and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided. | 2020-07-02 |
20200206280 | COMPOSITIONS COMPRISING A BACTERIAL STRAIN OF THE GENUS MEGASPHERA AND USES THEREOF - The invention provides compositions comprising bacterial strains for treating and preventing neurodegenerative disorders. | 2020-07-02 |
20200206281 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DEGENERATIVE MITRAL VALVE DISEASE IN A CANINE - The present invention relates to methods and compositions for diagnosing and treating degenerative mitral valve disease in a canine. In one embodiment, a method of diagnosing early stage degenerative mitral valve disease in a canine can comprise measuring a normalized relative abundance of a biomarker selected from the group consisting of | 2020-07-02 |
20200206282 | EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEI AND USE THEREOF - The present invention relates to an extracellular vesicle derived from | 2020-07-02 |
20200206283 | BACTERIAL POPULATIONS FOR PROMOTING HEALTH - A method of improving the glucose response in glucose tolerant and intolerant subjects is provided. The method comprises providing to the subject probiotic compositions, or agents which specifically reduce bacterial species. | 2020-07-02 |
20200206284 | TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION - Provided herein are compositions and methods for the treatment or prevention of pathogenic infections. | 2020-07-02 |
20200206285 | ONCOLYTIC VIRAL VECTORS AND USES THEREOF - The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. | 2020-07-02 |
20200206286 | REPLICATION-COMPETENT VESICULAR STOMATITIS VIRUSES - This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided. | 2020-07-02 |
20200206287 | Method and Compositions for Treating Viral Infection - A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae family, Flaviviridae family ( | 2020-07-02 |
20200206288 | Method and Compositions for Treating Viral Infection - A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae family, Flaviviridae family (Flavivirus genus), Deltaretrovirus genus, or Togaviriade family is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene. Alternatively, the composition comprises at least one, at least two, or at least three triterpenes. | 2020-07-02 |
20200206289 | COMPOSITION FOR PROMOTING PERIODONTAL REGENERATION - The present invention relates to a composition for promoting periodontal regeneration. The composition for promoting periodontal regeneration according to the present invention includes any one dicotyledon extract belonging to the order Campanula punctata, selected from the group consisting of Ussuri thistle extract, Helianthus annuus extract, Dandelion extract, Chrysanthemum extract, Arctium lappa extract, Common cosmos extract, Ligularia stenocephala extract, Foremost mugwort extract, Cichorium intybus extract, and mixture thereof. | 2020-07-02 |
20200206290 | COMPOSITIONS INCLUDING MILK THISTLE AND METHODS OF USE - In an embodiment, the present disclosure pertains to a dietary supplement including berberine in an amount up to about 1500 mg, cinnamon in an amount up to about 300 mg, chromium in an amount up to about 300 mcg, milk thistle in an amount up to about 150 mg, and pyrroloquinoline quinone disodium (PQQ) in an amount up to about 30 mg. Additionally, the present disclosure relates to a method for managing weight, maintaining healthy blood sugar levels, preventing diabetes, or alleviating symptoms associated with diabetes, including administering a composition to a subject. In some embodiments, the composition includes berberine in an amount up to about 1500 mg, cinnamon in an amount up to about 300 mg, chromium in an amount up to about 300 mcg, milk thistle in an amount up to about 150 mg, and PQQ in an amount up to about 30 mg. | 2020-07-02 |
20200206291 | COMPOSITION FOR PREVENTING OR TREATING OBESITY, COMPRISING SUPPLEMENT FOR REDUCING BODY FAT AND B-GLUCAN AS ACTIVE INGREDIENTS - The present invention relates to a composition for preventing or treating obesity, comprising a supplement for reducing body fat and a β-glucan as active ingredients. | 2020-07-02 |
20200206292 | Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof - Compositions and methods for bone health, cartilage health or both, are disclosed that include preparing and utilizing a mixture of at least one | 2020-07-02 |
20200206293 | METHOD FOR ENHANCING NITRIC OXIDE LEVELS IN A USER - A method for enhancing the nitric oxide levels in a user. Nitric oxide can provide many benefits to a user including, but not limited to, improved sleeping quality, regulation of blood pressure, and strengthening of the immune system. A quantity of bacopa monnieri and a quantity of consumable produce is heterogeneously combined together into a supplement mixture. A daily dosage of the supplement mixture is administered to a user daily in order enhance the nitric oxide levels of the user. The enhancement of nitric oxide levels provides many benefits as mentioned previously and additional benefits such as, but not limited to, increasing brain function and improving memory. | 2020-07-02 |
20200206294 | ALOE-HYPLEX TOPICAL FORMULATION AND A METHOD OF PREPARATION - The present invention relates to aloe-hyplex topical formulation and a method of preparation for multilayer skin delivery of active ingredients to provide skin rejuvenating effect. The | 2020-07-02 |
20200206295 | Burn Remedy - The use any type of coconut oil immediately on a burn site following a burn incident, reduce and/or resolve the burning pain, and prevent skin blistering. Positive outcome is dependent on time lapse between burn occurrence and coconut oil application. For best result apply any type of coconut oil to the burn site immediately; but will still reduce the burning pain even if time has lapsed and blistering already occurred. A combination of application of cold water first then any coconut oil to a burn site immediately following burn injury reduced healing time. | 2020-07-02 |
20200206296 | TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PROTECTING JOINTS, METHOD FOR PRODUCING THE SAME AND USE THEREOF - The present invention relates to the field of health care food technology, specifically to a traditional Chinese medicine composition with a function of protecting joints, a use thereof, a method for producing the same and a health care food thereof. The Chinese medicine composition comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract. The composition of the present disclosure has a reasonable formulation, and the ingredients cooperate with each other to achieve functions of reducing arthrocele degree, decreasing arthritis index, ameliorating biochemical index of arthritis and reducing articular cavity area through various paths and at various levels. | 2020-07-02 |
20200206297 | COMPOSITIONS AND METHODS FOR TREATMENT OF ALCOHOL INDUCED LIVER INJURY - Methods for treating alcohol induced liver injury include administering to a subject an effective amount of a ginger-derived nanoparticle. Methods for decreasing nuclear factor erythroid-2 related factor (Nrf2) activation in a hepatocyte are also provided and include contacting the hepatocyte with an effective amount of a ginger-derived nanoparticle. Pharmaceutical preparations including ginger-derived nanoparticles are further provided. | 2020-07-02 |
20200206298 | LISINOPRIL FORMULATIONS - Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction. | 2020-07-02 |
20200206299 | INHIBITORS OF BETA-ARRESTIN-NEUROKININ 1 RECEPTOR INTERACTIONS FOR THE TREATMENT OF PAIN - The present invention relates to compounds and their uses. In particular, to compounds that inhibit the interaction between β-arrestin and the intracellular C-terminus of the activated NK1R and their use in the treatment of pain. | 2020-07-02 |
20200206300 | AGENT FOR PROMOTING SKELETAL MUSCLE INJURY REPAIR - The present invention provides an agent for promoting skeletal muscle injury repair which agent comprises at least one peptide selected from the following (1) to (4):
| 2020-07-02 |
20200206301 | JNK Inhibitor Molecules For Treatment Of Various Diseases - The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy. | 2020-07-02 |
20200206302 | USE OF DES-ASPARTATE-ANGIOTENSIN I TO TREAT PATIENTS EXHIBITING INFLAMMATORY DISEASES AND THEIR SYMPTOMS - The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions. | 2020-07-02 |
20200206303 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING ENDOMETRIOSIS - The present disclosure provides improved methods of providing endometriosis testing to patients, as well as improved methods of monitoring and adjusting endometriosis treatments. | 2020-07-02 |
20200206304 | METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY THROUGH MULTIPLE BIO BARRIERS - Mini nanodrugs that include a polymalic-based molecular scaffold with one or more peptides capable of crossing the blood-brain barrier, one or more plaque-binding peptides and one or more therapeutic agents attached to the scaffold are provided. Methods of treating brain diseases or abnormal conditions, and imaging of the same in a subject by administering the mini nanodrugs are described. Methods for reducing formation of amyloid plaques in the brain of a subject are disclosed. | 2020-07-02 |
20200206305 | Granular Pharmaceutical Composition - The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function. | 2020-07-02 |
20200206306 | SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAs). | 2020-07-02 |
20200206307 | COMPOSITIONS FOR INCREASING RESILIENCE TO TRAUMATIC BRAIN INJURY - Provided herein are methods, compositions, and uses thereof for preventing traumatic brain injury (TBI) in a subject, wherein a composition comprising whey protein isolate and/or whey protein concentrate may be administered to a subject pre-injury, thereby increasing resilience of the subject to TBI. | 2020-07-02 |
20200206308 | SUPPRESSION OF ALLERGIC LUNG INFLAMMATION AND HYPERREACTIVITY - This disclosure relates to compositions of isolated polypeptides and methods of their use for the treatment and prevention of disease or disease symptoms associated with MARCKS phosphorylation and/or dissociation from the cell membrane, including but not limited to allergic inflammation, asthma, chronic bronchitis, COPD, infection, hyper-reactivity, cystic fibrosis, ulcerative colitis, Crohn's disease, irritable bowel syndrome, rosacea, eczema, psoriasis, acne, arthritis, rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. | 2020-07-02 |
20200206309 | METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS - Provided herein are methods and compositions for treating a Nurr1-mediated and/or PPAR-mediated condition. Also provided herein are methods and compositions for increasing Nurr1 or PPAR activity and/or levels in a cell. | 2020-07-02 |
20200206310 | HEMICHANNEL EXTRACELLULAR-DOMAIN SPECIFIC AGENTS FOR TREATING SEPSIS - Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein. | 2020-07-02 |
20200206311 | COMPOSITION INCLUDING MELITTIN FOR REMOVING M2-TYPE TUMOR-ASSOCIATED MACROPHAGE - The present invention relates to a composition including melittin as an active ingredient for removing an M2-type tumor-associated macrophage (TAM), and more specifically, the present invention relates to a composition exhibiting an effect of selectively suppressing only M2-type tumor-associated macrophages among tumor-associated macrophages. The composition according to the present invention only suppresses M2-type tumor-associated macrophages without affecting M1-type tumor-associated macrophages or cancer cells, thus exhibiting anti-cancer and metastasis suppressing effects by blocking angiogenesis through control of the microenvironment of cancer cells, while reducing the side-effects of existing anti-cancer effects. | 2020-07-02 |
20200206313 | POLYPEPTIDE NANOTUBES LINKED BY DISULFIDE BONDS FOR TARGETED DELIVERY OF CYTOTOXIC THERAPIES - Provided herein is a self-assembling polypeptide-based nanotube system having the ability to target cancer cells. The nanotubes target the cancer cell surface through integrin engagement with the help of multiple RGD units present along their surface and release their drug payload in a sustained manner. In addition, the nanotubes can be utilized for cellular imaging using any covalently tagged fluorescent dye. Provided herein is a self-assembling polypeptide-based nanotube system having the ability to target cancer cells. The nanotubes target the cancer cell surface through integrin engagement with the help of multiple RGD units present along their surface and release their drug payload in a sustained manner. In addition, the nanotubes can be utilized for cellular imaging using any covalently tagged fluorescent dye. | 2020-07-02 |
20200206314 | HSV VECTORS FOR DELIVERY OF NT3 AND TREATMENT OF CIPN - Disclosed herein are compositions and methods for treating neuropathy, embodiments, HSV vectors are provided comprising nucleic acid molecules encoding neurotrophins, such as neurotrophin 3 (NT3). | 2020-07-02 |
20200206315 | COMPOSITIONS AND METHODS COMPRISING BONE MORPHOGENETIC PROTEIN AND NEMO BINDING PEPTIDE - An osteogenic composition for implantation at or near a target tissue site beneath the skin is provided, the osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site. In some embodiments, a method is provided for treating a target tissue site in a patient in need of such treatment, the method comprising implanting an osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site. | 2020-07-02 |
20200206316 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY - Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. | 2020-07-02 |
20200206317 | COMPOSITIONS AND METHODS FOR INDUCED BROWN FAT DIFFERENTIATION - The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm16 and C/EBPβ activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm16 and C/EBPβ expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm16 and C/EBPβ expression and/or activity. | 2020-07-02 |
20200206318 | TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF - The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII). | 2020-07-02 |
20200206320 | Oral Care Compositions - An oral care composition, including a catalyzing enzyme and an anhydrous matrix configured to at least partially stabilize the catalyzing enzyme, wherein the anhydrous matrix includes a source of hydrogen peroxide, an acyl donor, a non-aqueous anhydrous liquid, and a surfactant mixture including sodium lauryl sulfate (SLS), Betaine, and a poloxamer. | 2020-07-02 |
20200206321 | METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS - Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries. | 2020-07-02 |
20200206322 | TREATING CANCER WITH CAS ENDONUCLEASE COMPLEXES - The invention generally relates to compositions and methods for targeted delivery of a Cas endonuclease or nucleic acid encoding a Cas endonuclease to a fusion sequence in a cancer cell but not in a healthy cell of a subject. The Cas endonuclease or nucleic acid encoding the Cas endonuclease may be complexed with a guide RNA complementary to a fusion sequence identified based on differences between a mutated sequence obtained from a cancer cell and a wild-type sequence obtained from a healthy cell of the subject. For example, the Cas endonuclease may be a Cas9 and cut DNA or a Cas13a and cut RNA. The Cas endonuclease complexes may induce cell death or cancerous cells or cause other beneficial effects. | 2020-07-02 |
20200206323 | AN AGENT, A DEVICE AND A BLOOD-CIRCULATION SYSTEM FOR TREATING LYSOSOMAL STORAGE DISEASES, AND A METHOD FOR TREATING LYSOSOMAL STORAGE DISEASES - A therapeutic agent containing, as an effective component, a glycolytic enzyme which is different from a deficient protein of a patient with lysosomal storage disease as a subject and/or a glycolytic enzyme which does not have a mannose 6-phosphate moiety or a mannose moiety. | 2020-07-02 |
20200206324 | METHOD FOR REGULATING AND CONTROLLING GLP-1/GLP-1R AND DRUG - The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition. | 2020-07-02 |
20200206325 | SYSTEMS AND METHODS FOR PREPARING A THROMBIN SERUM - A system for preparing a thrombin serum that can include a containment device, a cage received within the containment device, a cap attachable to the containment device, an inlet port configured to introduce a non-anti-coagulated autologous blood fluid into the containment device, and an outlet port. An activator, such as glass beads, can be present within the containment device. | 2020-07-02 |
20200206326 | Clostridium Histolyticum Enzymes and Methods for the Use Thereof - The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration. | 2020-07-02 |
20200206327 | HIPPO PATHWAY DEFICIENCY REVERSES SYSTOLIC HEART FAILURE POST-INFARCTION - Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example. | 2020-07-02 |
20200206328 | COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR EARLY INTERVENTION IN BONE MARROW TRANSPLANTATION AND TREATMENT OF GRAFT VERSUS HOST DISEASE - Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (α1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT. | 2020-07-02 |
20200206329 | NUCLEOTIDE SEQUENCE EXPRESSING AN EXOSOME-ANCHORING PROTEIN FOR USE AS VACCINE - The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine. | 2020-07-02 |
20200206330 | PARTNER OF SLD FIVE 1 (PSF1)-DERIVED PEPTIDE - A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described. | 2020-07-02 |
20200206331 | AN IMMUNOGENIC COMPOSITION HAVING IMPROVED STABILITY, ENHANCED IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR PREPARATION THEREOF - An immunogenic composition comprising of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen, Hepatitis B surface antigen (HBsAg), inactivated whole-cell | 2020-07-02 |
20200206332 | COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER - Provided are methods for sensitizing gastrin-associated tumors and/or cancers in subjects to inducers of humoral and cellular immune responses. In some embodiments, the methods relate to administering compositions that have anti-gastrin antibodies, gastrin peptides, and/or nucleic acids that inhibit expression of gastrin gene products to subjects. Also provided are methods for preventing, reducing, and/or eliminating the formation of fibroses associated with tumors and/or cancers, and methods for treating gastrin-associated tumors and/or cancers that include administering to subjects in need thereof a first agent that provides and/or induces an anti-gastrin humoral or cellular immune response in the subject and a second agent that includes one or more stimulators of cellular immune responses against the tumors and/or cancers. | 2020-07-02 |
20200206333 | COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE - Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse. | 2020-07-02 |
20200206334 | REPLICATION-DEFICIENT ARENAVIRUS PARTICLES AND TRI-SEGMENTED ARENAVIRUS PARTICLES AS CANCER VACCINES - The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable as vaccines and/or for treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with a chemotherapeutic agent, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof. | 2020-07-02 |
20200206335 | IMMUNOGENIC COMPOSITION COMPRISING A FUSION PEPTIDE DERIVED FROM SUPERANTIGEN TOXOIDS - The present disclosure provides immunogenic compositions useful in prevention and treatment of | 2020-07-02 |
20200206336 | A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS - The present invention pertains to a vaccine comprising an IgM protease antigen of | 2020-07-02 |
20200206337 | LIVE ATTENUATED VACCINES - The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of:
| 2020-07-02 |